NeoGenomics, Inc. (NASDAQ:NEO) has received an average recommendation of “Buy” from the ten ratings firms that are covering the firm, Marketbeat reports. Five investment analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $16.80.
A number of equities research analysts recently weighed in on the company. Royal Bank of Canada set a $23.00 price target on NeoGenomics and gave the company an “outperform” rating in a report on Wednesday. Scotiabank set a $22.00 price target on NeoGenomics and gave the company an “outperform” rating in a report on Wednesday. CIBC set a $19.00 price target on NeoGenomics and gave the company a “neutral” rating in a report on Wednesday. BidaskClub cut NeoGenomics from a “buy” rating to a “hold” rating in a report on Thursday, December 21st. Finally, Janney Montgomery Scott reaffirmed a “buy” rating on shares of NeoGenomics in a report on Thursday, October 26th.
NeoGenomics (NASDAQ:NEO) traded up $0.01 during trading on Monday, hitting $8.58. The company had a trading volume of 124,166 shares, compared to its average volume of 200,633. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.14 and a quick ratio of 1.99. The company has a market cap of $689.91, a P/E ratio of -24.51, a PEG ratio of 3.52 and a beta of 0.84. NeoGenomics has a 1-year low of $7.12 and a 1-year high of $11.63.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Royce & Associates LP increased its stake in shares of NeoGenomics by 57.5% in the 2nd quarter. Royce & Associates LP now owns 955,900 shares of the medical research company’s stock valued at $8,565,000 after buying an additional 348,900 shares during the period. Goldman Sachs Group Inc. increased its stake in shares of NeoGenomics by 79.2% in the 2nd quarter. Goldman Sachs Group Inc. now owns 30,678 shares of the medical research company’s stock valued at $275,000 after buying an additional 13,561 shares during the period. Uniplan Investment Counsel Inc. increased its stake in shares of NeoGenomics by 7.1% in the 3rd quarter. Uniplan Investment Counsel Inc. now owns 839,310 shares of the medical research company’s stock valued at $9,341,000 after buying an additional 55,506 shares during the period. Columbus Circle Investors acquired a new stake in shares of NeoGenomics in the 3rd quarter valued at $4,779,000. Finally, PEAK6 Investments L.P. acquired a new stake in shares of NeoGenomics in the 3rd quarter valued at $592,000. 83.43% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “NeoGenomics, Inc. (NEO) Receives $10.00 Average Target Price from Analysts” was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.tickerreport.com/banking-finance/3126002/neogenomics-inc-neo-receives-10-00-average-target-price-from-analysts.html.
NeoGenomics Company Profile
NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.